Physician profile
Adebowale Prest
NPI 1326030438
$1,769.71
in general payments reported to CMS, 2019-2025
22 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $79.87 · 2021: $85.30 · 2022: $222 · 2023: $565 · 2024: $345 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.41 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $227.08 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $212.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $172.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $143.72 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lilly USA, LLC | $143.42 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Medtronic, INC. | $137.27 | 2022-2024 | Propel |
| Pfizer INC. | $121.89 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $120.08 | 2020-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $77.10 | 2019-2025 | Breztri |
| Horizon Therapeutics Plc | $64.79 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $48.89 | 2019-2023 | |
| Exact Sciences Corporation | $46.99 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.04 | 2019-2023 | |
| Sanofi Pasteur INC. | $41.58 | 2023-2024 | |
| Glaxosmithkline, LLC. | $41.08 | 2022-2023 | Shingrix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.05 | 2023 | Gemtesa |
| Insulet Corporation | $21.19 | 2022 | |
| Abbott Laboratories | $17.24 | 2022 | |
| Abbvie INC. | $16.74 | 2023 | |
| Irhythm Technologies, INC. | $16.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.89 | 2019 | |
| Neurocrine Biosciences, INC. | $13.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adebowale Prest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.